Abogen Bioscience

Abogen Bioscience is a clinical-stage biotechnology company specializing in the development of mRNA-based therapeutics and vaccines. Founded in 2019 and headquartered in Suzhou, China, the company utilizes a proprietary lipid nanoparticle (LNP) delivery platform to create treatments for infectious diseases, oncology, and rare diseases. Its most prominent program is AWcorna (ARCoV), an mRNA COVID-19 vaccine developed in collaboration with Walvax Biotechnology and the Academy of Military Medical Sciences. Abogen has raised significant capital from global investors to scale its R&D pipeline and establish large-scale GMP manufacturing capabilities. The company's technology focuses on enhancing mRNA stability and delivery efficiency to improve therapeutic outcomes.